Donor-derived b2a2-specific T cells for immunotherapy of patients with chronic myeloid leukemia

Journal of Immunotherapy

Volumn 25, Issue 6, 2002, Pages 469-475

  Crough, Tania ^a   Nieda, Mie ^a   Morton, James ^a   Bashford, John ^a   Durrant, Simon ^a   Nicol, Andrew J ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

b2a2; Chronic myeloid leukemia; Dendritic cell; Immunotherapy; T cells

Indexed keywords

BCR ABL PROTEIN; HLA DR7 ANTIGEN;

ALLOGRAFT; ARTICLE; CELL STIMULATION; CHRONIC MYELOID LEUKEMIA; DENDRITIC CELL; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; FEASIBILITY STUDIES; FUSION PROTEINS, BCR-ABL; GRAFT VS LEUKEMIA EFFECT; HLA-DR7 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-4; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LYMPHOCYTE TRANSFUSION; MONOCYTES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036844393     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200211000-00003     Document Type: Article

References (26)

1. Grosveld G, Verwoerd T, van Agthoven T, et al. The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript. Mol Cell Biol 1986;6:607-16.
2. Heisterkamp N, Stam K, Groffen J, et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985; 315:758-61.
3. Lee MS, LeMaistre A, Kantarjian HM, et al. Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. Blood 1989;73:2165-70.
4. Miyamura K, Tahara T, Tanimoto M, et al. Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients. Blood 1993;81:1089-93.
5. Collins RH, Jr., Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44.
6. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5.
7. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999;94:1201-8.
8. + hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 1995;55:1099-104.
9. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-7.
10. Nieda M, Nicol A, Kikuchi A, et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998;91:977-83.
11. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 1999;93:2411-9.
12. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-51.
13. Thumer B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190: 1669-78.
14. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996;87:3587-92.
15. Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998;101:2290-6.
16. ten Bosch GJ, Kessler JH, Joosten AM, et al. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood 1999;94:1038-45.
17. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1991. WHO Nomenclature Committee for factors of the HLA system. Tissue Antigens 1992;39:161-73.
18. Champlin R, Jansen J, Ho W, et al. Retention of graft-versus-leukemia using selective depletion of CD8- positive T lymphocytes for prevention of graft-versus-host disease after bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc 1991;23:1695-6.
19. + T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 1996;93:606-12.
20. Sosman JA, Oettel KR, Smith SD, et al. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are cross-reactive with determinants present on unrelated nonleukemic cells. Blood 1990;75:2005-16.
21. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86:4337-43.
22. Nimer SD, Giorgi J, Gajewski JL, et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 1994;57:82-7.
23. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46.
24. Barrett AJ. Mechanisms of the graft-versus-leukemia reaction. Stem Cells 1997;15:248-58.
25. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001;22: 269-76.
26. Mannering SI, McKenzie JL, Fearnley DB, et al. HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. Blood 1997;90: 290-7.